Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Remogliflozin SCHEMBL2253397 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL18629779 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL17034639 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL2378682 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL3730054 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL16153590 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL18629778 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL16155105 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL17127189 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Remogliflozin SCHEMBL13258819 | 0.95 | SLC5A2 (0.90) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361289-A1 | TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361289-A1 | TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS | SLC5A2, SLC5A1, GPR119 | SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.